Subscribe to our Newsletters !!
Infections pose an everpresent threat to society a
Biotech Fluidics has introduced a durable dual sta
A new COVID-19 variant, BA.3.2, informally called
The sustained tensions between Iran and the United
For a number of years now, healthcare systems glob
Tofu used to be associated with Asian cuisine, but
Dear Readers, Welcome to a fresh and forward-lo
New Delhi, Dec 30 (PTI) Drug firm Zydus Cadila on Wednesday said it has received approval from the Drug Controller General of India (DCGI) for Saroglitazar Mg, used for the treatment of non-alcoholic fatty liver disease (NAFLD), in the nation. Zydus Cadila explained the prevalence of NAFLD in India is estimated to be nearly 25-30 percent of the overall population.
This NAFLD condition could progress to NASH, cirrhosis and liver failure.
It’s a large unmet medical need as there is currently no approved drug for the treatment of NAFLD and NASH anywhere in the world, Zydus Cadila said.
Pankaj Patel, the Chairman of Zydus Group, stated with Saroglitazar Mg, the company has managed to successfully provide an innovative medicine for dealing with chronic liver diseases like NAFLD and NASH and helping patients in leading healthier lives.
In March 2020, Saroglitazar Mg had received approval for the treatment of NASH. PTI SVK MR MR
